Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 23 , ISSUE 9 ( September, 2019 ) > List of Articles


Emergence of Burkholderia cepacia in ICU Setting

Suneeta Meena, Raunak Bir, Seema Sood, Bimal Kumar Das

Keywords : Burkholderia cepacia, Colistin, ICU

Citation Information : Meena S, Bir R, Sood S, Das BK. Emergence of Burkholderia cepacia in ICU Setting. Indian J Crit Care Med 2019; 23 (9):423-426.

DOI: 10.5005/jp-journals-10071-23237

License: CC BY-NC 4.0

Published Online: 01-09-2019

Copyright Statement:  Copyright © 2019; The Author(s).


Background: B. cepacia is metabolically versatile organism which is not only resistant to many antibiotics but also disinfectants. This makes their survival easy even in restricted areas like intensive care unit (ICU) and management difficult. Aims and objectives: To describe sudden emergence of Burkholderia at a tertiary care centre ICU setting in milieu of colistin usage Materials and methods: Cases were patients with culture proven B.cepacia. They were picked up as non-lactose fermenting, oxidase positive, motile, gram-negative bacilli which was resistant to colistin and aminoglycosides and sensitive to cotrimoxazole. These isolates were further confirmed by both VITEK-2 compact system (Biomerieux, France) and standard bacterial techniques. Colistin consumption data were retrospectively collected from medical store records of hospitals and individual ICU pharmacy records from January 2016 to June 2016, and were expressed as total dialy doses in a month per 1000 patient days (DDD/1000PD) Results: An increase was observed in B. cepacia infection linked to increased consumption of colistin in ICU. Conclusion: Based on these results an increase was observed in B.cepacia infection which correlated with increased consumption of colistin in ICU. We speculate that extensive use of colistin may lead to selection of intrinsically resistant B. cepacia and may facilitate their spread as nosocomial pathogens.

PDF Share
  1. Mortensen JE, Fisher MC, LiPuma JJ. Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment. Infect Control Hosp Epidemiol 1995;16:30–32.
  2. Huang CH, Jang TN, Liu CY, Fung CP, Yu KW, Wong WW. Characteristics of patients with Burkholderia cepacia bacteremia. J Microbiol Immunol Infect 2001;34:215–219.
  3. Siddiqui AH, Mulligan ME, Mahenthiralingam E, Hebden J, Brewrink J, Qaiyumi S, et al. An episodic outbreak of genetically related Burkholderia cepacia among non-cystic fi brosis patients at a university hospital. Infect Control Hosp Epidemiol 2001;22:419 – 22.
  4. Estivariz CF, Bhatti LI, Pati R, Jensen B, Arduino MJ, Jernigan D, et al. An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest 2006;130:1346–1353.
  5. Nasser RM, Rahi AC, Haddad MF, Daoud Z, Irani-Hakime N, Almawi WY. Outbreak of Burkholderia cepacia bacteremia traced to contaminated hospital water used for dilution of an alcohol skin antiseptic. Infect Control Hosp Epidemiol 2004;25:231–239.
  6. Zurita J, Mejia L, Zapata S, Trueba G, Vargas AC, Aguirre S, et al. Healthcare-associated respiratory tract infection and colonization in an intensive care unit caused by Burkholderia cepacia isolated in mouthwash. Int J Infect Dis. 2014 Dec;29:96–99.
  7. Abat C, Desboves G, Olaitan AO, Chaudet H, Roattino N, Fournier PE, et al. Increasing burden of urinary tract infections due to intrinsic colistin-resistant bacteria in hospitals in Marseille, France. Int J Antimicrob Agents. 2015 Feb;45(2):144–150.
  8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-sixth informational supplement M100-S26. Wayne PA: Clinical and Laboratory Standards Institute; 2016.
  9. The nonfermentative gram negative bacilli In: Winn W AS, Jande W, Koneman E, Procop G, Schrekernbenger P, Woods G, editors. Konemans colour atlas and Textbook of Diagnostic Microbiology Baltimore, USA: Lippincolt Williams and Wilkins Publisher; 2006. vol- p. 303–391.
  10. Nasser RM, Rahi AC, Haddad MF, Daoud Z, Irani-Hakime [5] N, Almawi WY. Outbreak of Burkholderia cepacia bacteremia traced to contaminated hospital water used for dilution of an alcohol skin antiseptic. Infect Control Hosp Epidemiol 2004;25:231–239.
  11. Oie S, Kamiya A. Microbial contamination of antiseptics and disinfectants. Am J Infect Control,1996;24: 389–395.
  12. LiPuma JJ, Currie BJ, Lum G, Vandamme P Burkholderia, Stenotrophomonas, Ralstonia, et al. In Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, and Yolken RH, editors. Manual of clinical microbiology, ASM Press, Washington, DC 2007: 749–769.
  13. Mahenthiralingam E, Baldwin A, Dowson CG. Burkholderia cepacia complex bacteria opportunistic pathogens with important natural biology. J Appl Microbiol 2008;104:1539–1551.
  14. Burns JL, Wadsworth CD, Barry JJ, Goodall CP. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother 1996; 40: 307–313. 20.
  15. Menuet M, Bittar F, Stremler N, Dubus JC, Sarles J, Raoult D, et al. Firstisolation of two colistin-resistant emerging pathogens, Brevundimonas diminuta and Ochrobactrum anthropi, in a woman with cystic fibrosis: a case report. J Med Case Rep. 2008;2:373.
  16. Chen FL, Wang GC, Teng SO, Ou TY, Yu FL, Lee WS. Clinical and epidemiological of Chryseobacterium indologenes infections: analysis of 215 cases. J Microbiol Immunol Infect. 2013;46(6):425–432.
  17. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012;10(8):917–934.
  18. Dizbay M, Tunccan OG, Sezer BE, Aktas F, Arman D. Nosocomial Burkholderia cepacia infections in a Turkish university hospital: a five-year surveillance. J Infect Dev Ctries. 2009;3(4):273-7.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.